| Min Pa: | Min Pa(max): | Activity's type: |
| Ext | Pa | Pi | Pmax | Activity | Other Results | ID Pa_max |
|---|---|---|---|---|---|---|
| 0.643 | 0.006 | 0.643 | 5 Hydroxytryptamine release inhibitor | |||
| 0.597 | 0.019 | 0.597 | Aldehyde oxidase inhibitor | |||
| 0.48 | 0.017 | 0.48 | Cardiotonic | 0.289 0.061 DBMET02779 | ||
| 0.475 | 0.012 | 0.475 | Sigma receptor agonist | |||
| 0.434 | 0.005 | 0.434 | Tyrosine 3 hydroxylase inhibitor | |||
| 0.43 | 0.005 | 0.43 | Anesthetic local | |||
| 0.443 | 0.032 | 0.443 | Spasmolytic | |||
| 0.359 | 0.004 | 0.359 | Potassium channel (Ca-activated) activator | |||
| 0.345 | 0.011 | 0.345 | 5 Hydroxytryptamine 1E antagonist | |||
| 0.32 | 0.002 | 0.32 | 5 Hydroxytryptamine 4 antagonist | |||
| 0.377 | 0.072 | 0.377 | GABA C receptor rho-3 antagonist | |||
| 0.319 | 0.029 | 0.319 | MAP kinase kinase 2 inhibitor | |||
| 0.32 | 0.038 | 0.32 | Psychostimulant | |||
| 0.315 | 0.046 | 0.315 | Superoxide dismutase inhibitor | |||
| 0.275 | 0.011 | 0.275 | Alpha 2b adrenoreceptor antagonist | |||
| 0.28 | 0.017 | 0.28 | Nitric-oxide synthase stimulant | |||
| 0.263 | 0.004 | 0.263 | Acetylcholine release stimulant | |||
| 0.257 | 0.01 | 0.257 | 5 Hydroxytryptamine agonist | |||
| 0.278 | 0.032 | 0.278 | Neuropeptide Y2 antagonist | |||
| 0.313 | 0.079 | 0.313 | Calcium channel activator | |||
| 0.235 | 0.005 | 0.235 | Potassium channel large-conductance Ca-activated activator | |||
| 0.331 | 0.109 | 0.331 | Histamine release inhibitor | |||
| 0.233 | 0.025 | 0.233 | Nav1.2 sodium channel blocker | |||
| 0.232 | 0.026 | 0.232 | Heat shock protein 90 antagonist | |||
| 0.291 | 0.099 | 0.291 | Transcription factor NF kappa B inhibitor | |||
| 0.195 | 0.026 | 0.195 | Nav1.3 sodium channel blocker | |||
| 0.21 | 0.048 | 0.21 | Tumour necrosis factor antagonist | |||
| 0.185 | 0.025 | 0.185 | Cyclooxygenase 3 inhibitor | |||
| 0.185 | 0.027 | 0.185 | Chelator | |||
| 0.187 | 0.037 | 0.187 | Acetylcholinesterase inhibitor | |||
| 0.208 | 0.063 | 0.208 | Focal adhesion kinase 2 inhibitor | |||
| 0.142 | 0.002 | 0.142 | 5 Hydroxytryptamine 4 agonist | |||
| 0.261 | 0.123 | 0.261 | Vasodilator, coronary | |||
| 0.19 | 0.055 | 0.19 | Heat shock protein 90 alpha antagonist | |||
| 0.178 | 0.044 | 0.178 | GABA C receptor rho-2 antagonist | |||
| 0.207 | 0.074 | 0.207 | Amyloid beta aggregation inhibitor | |||
| 0.168 | 0.036 | 0.168 | DNA intercalator | |||
| 0.214 | 0.083 | 0.214 | Peptidyltransferase inhibitor | |||
| 0.191 | 0.062 | 0.191 | Lipocortins synthesis antagonist | |||
| 0.157 | 0.032 | 0.157 | Butyrylcholinesterase inhibitor | |||
| 0.13 | 0.012 | 0.13 | 5 Hydroxytryptamine 3 antagonist | |||
| 0.175 | 0.059 | 0.175 | Cholinergic | |||
| 0.149 | 0.033 | 0.149 | Alpha 2c adrenoreceptor antagonist | |||
| 0.146 | 0.032 | 0.146 | Carbonic anhydrase XV inhibitor | |||
| 0.12 | 0.007 | 0.12 | Heat shock protein 90 beta antagonist | |||
| 0.202 | 0.089 | 0.202 | Ca2+/calmodulin-dependent kinase I alpha inhibitor | |||
| 0.137 | 0.025 | 0.137 | Electrolyte absorption antagonist | |||
| 0.206 | 0.096 | 0.206 | Antiamyloidogenic | |||
| 0.263 | 0.154 | 0.263 | 15-Lipoxygenase inhibitor | |||
| 0.136 | 0.028 | 0.136 | Folate antagonist | |||
| 0.121 | 0.019 | 0.121 | Myeloperoxidase inhibitor | |||
| 0.106 | 0.006 | 0.106 | Epithelial sodium channel blocker | |||
| 0.174 | 0.075 | 0.174 | MAP kinase kinase 5 inhibitor | |||
| 0.2 | 0.1 | 0.2 | Glucose-6-phosphate dehydrogenase-6-phosphogluconolactonase inhibitor | |||
| 0.185 | 0.088 | 0.185 | Proto-oncogene tyrosine-protein kinase Fyn inhibitor | |||
| 0.165 | 0.069 | 0.165 | Interleukin 6 antagonist | |||
| 0.192 | 0.098 | 0.192 | ErbB-1 antagonist | |||
| 0.167 | 0.073 | 0.167 | Src kinase inhibitor | |||
| 0.132 | 0.038 | 0.132 | Platelet activating factor alpha antagonist | |||
| 0.102 | 0.015 | 0.102 | 5 Hydroxytryptamine 3A antagonist | |||
| 0.213 | 0.128 | 0.213 | 5 Hydroxytryptamine uptake stimulant | |||
| 0.163 | 0.079 | 0.163 | Catenin beta inhibitor | |||
| 0.087 | 0.006 | 0.087 | Ryanodine receptor antagonist | |||
| 0.201 | 0.12 | 0.201 | MAP kinase kinase 3 inhibitor | |||
| 0.287 | 0.209 | 0.287 | Caspase 9 stimulant | |||
| 0.119 | 0.042 | 0.119 | Sphingomyelinase inhibitor | |||
| 0.229 | 0.164 | 0.229 | Calpain 2 inhibitor | |||
| 0.166 | 0.104 | 0.166 | DNA methylase inhibitor | |||
| 0.122 | 0.062 | 0.122 | Platelet activating factor antagonist | |||
| 0.165 | 0.104 | 0.165 | I kappa B kinase epsilon inhibitor | |||
| 0.092 | 0.036 | 0.092 | Estrogen-related receptor beta agonist | |||
| 0.072 | 0.016 | 0.072 | Topoisomerase II beta inhibitor | |||
| 0.111 | 0.055 | 0.111 | Urease inhibitor | |||
| 0.069 | 0.013 | 0.069 | Sodium/calcium exchanger inhibitor | |||
| 0.159 | 0.104 | 0.159 | Non-steroidal antiinflammatory agent | |||
| 0.143 | 0.088 | 0.143 | CF transmembrane conductance regulator agonist | |||
| 0.153 | 0.099 | 0.153 | Death-associated protein kinase 2 inhibitor | |||
| 0.125 | 0.071 | 0.125 | c-Src kinase inhibitor | |||
| 0.152 | 0.099 | 0.152 | Amyloid beta precursor protein antagonist | |||
| 0.15 | 0.102 | 0.15 | ATPase inhibitor | |||
| 0.09 | 0.042 | 0.09 | Alpha 2a adrenoreceptor antagonist | |||
| 0.115 | 0.067 | 0.115 | 5 Hydroxytryptamine antagonist | |||
| 0.201 | 0.156 | 0.201 | Ca2+/calmodulin-dependent kinase II alpha inhibitor | |||
| 0.095 | 0.05 | 0.095 | NADH dehydrogenase inhibitor | |||
| 0.056 | 0.012 | 0.056 | 5 Hydroxytryptamine 3B antagonist | |||
| 0.197 | 0.154 | 0.197 | Gastrin inhibitor | |||
| 0.103 | 0.06 | 0.103 | Platelet activating factor beta antagonist | |||
| 0.124 | 0.082 | 0.124 | Lck kinase inhibitor | |||
| 0.112 | 0.069 | 0.112 | 5 Hydroxytryptamine 2B antagonist | |||
| 0.074 | 0.034 | 0.074 | Potassium channel (ATP-sensitive) blocker | |||
| 0.092 | 0.053 | 0.092 | Insulin growth factor antagonist | |||
| 0.188 | 0.151 | 0.188 | Transcription factor STAT3 inhibitor | |||
| 0.097 | 0.06 | 0.097 | Fibroblast growth factor 1 antagonist | |||
| 0.093 | 0.056 | 0.093 | Polo-like kinase-1 inhibitor | |||
| 0.087 | 0.052 | 0.087 | Insulin like growth factor 1 antagonist | |||
| 0.107 | 0.072 | 0.107 | Interleukin 2 antagonist | |||
| 0.086 | 0.051 | 0.086 | Platelet growth factor antagonist | |||
| 0.086 | 0.052 | 0.086 | D-Ala-D-Ala ligase inhibitor | |||
| 0.144 | 0.11 | 0.144 | DNA methyltransferase I inhibitor | |||
| 0.105 | 0.071 | 0.105 | Mucolytic | |||
| 0.066 | 0.034 | 0.066 | Corticotropin releasing factor 2 receptor antagonist | |||
| 0.097 | 0.065 | 0.097 | Glutamate (mGluR7) agonist | |||
| 0.075 | 0.043 | 0.075 | Phospholipase D inhibitor | |||
| 0.234 | 0.202 | 0.234 | DNA directed DNA polymerase inhibitor | |||
| 0.125 | 0.095 | 0.125 | Peroxidase inhibitor | |||
| 0.173 | 0.144 | 0.173 | Calpain inhibitor | |||
| 0.048 | 0.019 | 0.048 | Plasmepsin II inhibitor | |||
| 0.082 | 0.054 | 0.082 | Adrenaline agonist | |||
| 0.255 | 0.227 | 0.255 | MAP kinase 1 inhibitor | |||
| 0.048 | 0.021 | 0.048 | Dihydrofolate reductase inhibitor | |||
| 0.062 | 0.035 | 0.062 | Fibroblast growth factor 4 antagonist | |||
| 0.047 | 0.021 | 0.047 | Alpha 1L adrenoreceptor agonist | |||
| 0.145 | 0.12 | 0.145 | Anesthetic general | |||
| 0.065 | 0.041 | 0.065 | Dopamine D3 antagonist | |||
| 0.066 | 0.041 | 0.066 | Beta 3 adrenoreceptor antagonist | |||
| 0.088 | 0.066 | 0.088 | Glutamate release inhibitor | |||
| 0.072 | 0.051 | 0.072 | Telomerase inhibitor | |||
| 0.062 | 0.041 | 0.062 | Beta 2 adrenoreceptor agonist | |||
| 0.111 | 0.091 | 0.111 | Ca2+/calmodulin-dependent kinase II delta inhibitor | |||
| 0.059 | 0.041 | 0.059 | Gonadotropin-releasing hormone receptor agonist | |||
| 0.065 | 0.048 | 0.065 | Purinergic P2X2 antagonist | |||
| 0.092 | 0.075 | 0.092 | GABA C receptor rho-1 antagonist | |||
| 0.047 | 0.033 | 0.047 | CC chemokine 4 receptor antagonist | |||
| 0.183 | 0.17 | 0.183 | Thyroid hormone beta antagonist | |||
| 0.186 | 0.174 | 0.186 | Thyroid hormone antagonist | |||
| 0.198 | 0.187 | 0.198 | Beta lactamase inhibitor | |||
| 0.164 | 0.154 | 0.164 | Interleukin agonist | |||
| 0.034 | 0.025 | 0.034 | Phosphoglycerate kinase inhibitor | |||
| 0.02 | 0.01 | 0.02 | Estrogen-related receptor gamma agonist | |||
| 0.059 | 0.05 | 0.059 | Dopamine D2 antagonist | |||
| 0.045 | 0.038 | 0.045 | Benzodiazepine antagonist | |||
| 0.112 | 0.107 | 0.112 | Activin receptor-like kinase 2 inhibitor | |||
| 0.064 | 0.059 | 0.064 | Dopamine antagonist | |||
| 0.084 | 0.079 | 0.084 | MAP kinase kinase 1 inhibitor | |||
| 0.076 | 0.072 | 0.076 | Alpha 2 adrenoreceptor antagonist | |||
| 0.08 | 0.076 | 0.08 | Potassium channel activator | |||
| 0.062 | 0.07 | 0.071 | Nav1.8 sodium channel blocker | 0.071 0.054 DBMET02779 | DBMET02779 | |
| 0.048 | 0.245 | 0.099 | ABCA1 expression enhancer | 0.099 0.051 DBMET02779 | DBMET02779 | |
| 0.009 | 0.211 | 0.028 | Liver X receptor antagonist | 0.028 0.025 DBMET02779 | DBMET02779 | |
| 0.015 | 0.429 | 0.071 | Calcium-independent phospholipase A2 inhibitor | 0.071 0.002 DBMET02779 | DBMET02779 | |
| 0.002 | 0.665 | 0.018 | Calcium-dependent phospholipase A2 inhibitor | 0.018 0.005 DBMET02779 | DBMET02779 | |
| 0.021 | 0.924 | 0.12 | NOS3 expression enhancer | 0.12 0.114 DBMET02779 | DBMET02779 | Ext | Pa | Pi | Pmax | Activity | Other Results | ID Pa_max |